Rockwell Medical Inc (RMTI) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Rockwell Medical Inc $4.47, price $8.65, upside -48.3%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range $0.5505 – $9.68 · fair‑value band $2.95 – $5.58 · the $8.65 price screens above the $4.47 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Rockwell Medical in your weekly email
Every Wednesday you see whether Rockwell Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.
Show more
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Stock analysis
Rockwell Medical Inc (RMTI) currently trades at $8.65, while our model-based Fair Value estimate is $4.47, 48.3% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $2.95 (bear) to $5.58 (bull), the price of $8.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Rockwell Medical Inc reported revenue of $69.3M in FY2025 versus $61.9M in FY2021, a compound +2.8%/yr. Reported net income was −$5.3M in FY2025.
Key figures
Market cap $34.2M · P/S ratio 0.50 · EPS (TTM) $−1.32 · Net margin −7.7% · Return on equity −15.5% · Return on assets (EBIT) −23.7% · Operating margin −6.0% · Revenue (TTM) $69.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 2% below its 52-week high and 1,471% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −48%, RMTI screens richer than that median.
Fair Value models
Bear $2.95Fair Value $4.47Bull $5.58
Price $8.65 · Upside -48.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.10/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−31.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2020 (pandemic). Over 10 years: +2.3% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−45.7% (2020) → −6.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside−48.3% · Below median
Profitability
Return on assets−5.2% · Bottom 25%
Net margin (TTM)−7.3% · Bottom 25%
Operating margin (TTM)−6.0% · Bottom 25%
Growth and dividend
Revenue growth10.6% · Above median
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.93× · Cheaper than median
P/S (TTM)0.49× · Cheapest 25%
PEG4.43× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)53· sector 24
PAST (return on equity)0· sector 26
HEALTH (low debt)88· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Rockwell Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/RMTI
Frequently asked questions
Is Rockwell Medical Inc (RMTI) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $4.47 versus a price of $8.65, about −48% upside (overvalued).
What is the fair value of RMTI?
Our model-based fair value for Rockwell Medical Inc is $4.47 (as of Oct 4, 2026), built from audited fundamentals. The current price: $8.65.
What is the quality score of RMTI?
Rockwell Medical Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rockwell Medical Inc (RMTI)?
Our model-based price target is the fair value of $4.47 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario $2.95, optimistic scenario $5.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Rockwell Medical Inc stock forecast for 2026?
Our models put fair value at $4.47, about −48% upside versus a price of $8.65 (overvalued). Cautious scenario $2.95, optimistic scenario $5.58. The calculation is refreshed regularly with new filings.
What is the revenue of Rockwell Medical Inc (RMTI)?
Rockwell Medical Inc reported trailing-twelve-month revenue of about $69.4M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Rockwell Medical Inc (RMTI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rockwell Medical Inc it is $4.47 per share (as of Oct 4, 2026), against a price of $8.65. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Rockwell Medical Inc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, RMTI trades above its calculated fair value: price $8.65, fair value $4.47, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RMTI?
No. The price is what the market pays today ($8.65); the fair value is what the company's own numbers justify ($4.47). For Rockwell Medical Inc the two are $4.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rockwell Medical Inc worth?
The market values Rockwell Medical Inc at about $34.2M (market capitalisation, as of Oct 4, 2026). Per share that is $8.65; our models calculate a fair value of $4.47 per share.
What do the bullish and bearish scenarios say about RMTI?
Our models span a range for Rockwell Medical Inc: cautious scenario $2.95, base $4.47, optimistic $5.58 per share (as of Oct 4, 2026, price $8.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of RMTI?
The PEG ratio of Rockwell Medical Inc is 4.43 (P/E divided by earnings growth, as of Oct 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Rockwell Medical Inc (RMTI)?
Balance-sheet figures for Rockwell Medical Inc (as of Oct 4, 2026): return on equity −15.5%, debt of 0.24 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is RMTI from its 52-week high?
Rockwell Medical Inc trades at $8.65, about 2% below its 52-week high of $8.86 and 1,471% above the low of $0.5505 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $4.47 is for.
Which stocks are comparable to Rockwell Medical Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rockwell Medical Inc stock attractive at the current price?
The data as of Oct 4, 2026: price $8.65, calculated fair value $4.47 (−48%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RMTI calculated?
We run Rockwell Medical Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.47, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Rockwell Medical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rockwell Medical Inc (RMTI)?
The closing price on Oct 2, 2026 was $8.65. Our model-based fair value is $4.47, about −48% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rockwell Medical Inc right now?
The price sits above even our optimistic bull case ($5.58). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.95 to $5.58) leaves room in how you read the outcome.
Key figures of Rockwell Medical Inc
How large is the market capitalisation of Rockwell Medical Inc (RMTI)?
The market capitalisation of Rockwell Medical Inc is $34.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rockwell Medical Inc (RMTI)?
The price-to-sales ratio of Rockwell Medical Inc is 0.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rockwell Medical Inc (RMTI)?
Earnings per share at Rockwell Medical Inc are $−1.32. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rockwell Medical Inc (RMTI)?
The net margin of Rockwell Medical Inc is −7.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rockwell Medical Inc (RMTI)?
The return on equity (ROE) of Rockwell Medical Inc is −15.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rockwell Medical Inc (RMTI)?
On an EBIT basis the return on assets of Rockwell Medical Inc is −23.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rockwell Medical Inc (RMTI)?
The operating margin of Rockwell Medical Inc is −6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rockwell Medical Inc (RMTI)?
Revenue at Rockwell Medical Inc is growing +10.6% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rockwell Medical Inc (RMTI) generate?
The free cash flow of Rockwell Medical Inc is −$1.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rockwell Medical Inc (RMTI) carry?
The net debt of Rockwell Medical Inc is $1.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Rockwell Medical Inc in the live analysis
One click puts Rockwell Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 4, 2026